Abstract | BACKGROUND: OBSERVATIONS: CONCLUSION: A single infusion of infliximab at 5 to 10 mg/kg resulted in the rapid and complete clearing of recalcitrant psoriatic plaques and erythroderma with a disease-free interval of 3 to 4 months in these 2 patients and improved the symptoms of psoriatic arthritis.
|
Authors | Ryan P O'Quinn, Jami L Miller |
Journal | Archives of dermatology
(Arch Dermatol)
Vol. 138
Issue 5
Pg. 644-8
(May 2002)
ISSN: 0003-987X [Print] United States |
PMID | 12020227
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Tumor Necrosis Factor-alpha
- Infliximab
|
Topics |
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- Autoimmune Diseases
(drug therapy, pathology)
- Female
- Humans
- Infliximab
- Male
- Middle Aged
- Psoriasis
(drug therapy, pathology)
- Recurrence
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(immunology)
|